Ascendis Pharma heads into its September 4 earnings report with the analyst community firmly in the buy camp — but quietly marking down price targets even as the stock jumps.
The most striking development since the previous note is what happened on Monday. A cluster of firms — B of A Securities, Jefferies, and Stifel — all trimmed price targets on the same day while holding Buy ratings. None cut by more than $3-4. But the uniformity of the move is notable. It suggests the Street is calibrating downward modestly ahead of the print, not abandoning the thesis. The consensus remains Buy, with 15 analysts on that side, and the mean target of $270 sits only marginally above the current price of $263. TD Cowen and RBC had moved in the opposite direction just two weeks earlier — raising targets to $341 and $290 respectively — so the picture is one of a Street that was upgrading through August and has now paused to tighten expectations into the event.
The bull case centres on Ascendis's rare-disease pipeline and a long-run revenue target of €10 billion, with Phase 3 studies and regional exclusivity deals providing the runway. Bears counter with a more immediate concern: competitor VOXZOGO is entrenched in the growth hormone space, and the company remains heavily dependent on US reimbursement dynamics. The earnings surprise factor score ranks in the 95th percentile — the company has consistently beaten estimates — but EPS momentum over the past 90 days sits in just the 20th percentile, meaning forward estimate revisions have been soft even as the company delivers on reported numbers.
Options positioning has continued to tighten beyond what the prior note described. The put/call ratio has now reached 0.52, nearly two standard deviations above its 20-day average of 0.37. That is a meaningful step up from the 0.44 reading flagged on August 26, and now approaches levels last seen near the year's most defensive positioning. The stock itself has added 6% in a single session and is up about 8% on the month, so the hedging demand is running against a backdrop of genuine price strength — not fear of a falling stock. Short interest is up roughly 26% over the past month to around 3.75 million shares, but borrow remains loose. Availability is extremely wide at over 2,700%, and the cost to borrow at 0.47% is negligible. There is no meaningful squeeze pressure and no sign that short sellers are pressing an aggressive directional bet.
Insider activity adds a mild constructive note. Director Jean-Jacques Bienaime bought 2,000 shares across two transactions on August 14 at around $246, adding to a pattern of smaller purchases stretching back through May. The CFO also bought in June. Net insider purchases over the past 90 days total roughly $777,000 — modest in dollar terms, but consistent in direction. T. Rowe Price holds nearly a quarter of the company's shares and added over 8 million shares in the most recently reported period, making institutional conviction hard to ignore as context.
The September 4 print will ultimately test whether the company's commercial momentum in its rare-disease portfolio is strong enough to validate the upper end of that analyst target range — and whether a stock that has just jumped 6% in a session can absorb the weight of defensive options positioning that has quietly built around it.
See the live data behind this article on ORTEX.
Open ASND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
